You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Use of a Hemoglobin-Based Oxygen Carrier in the Treatment of Severe Anemia

Shander, Aryeh MD*; Alalawi, Raed MD†; Seeber, Petra MD‡; Lui, John MD*

Obstetrics & Gynecology:
Case Reports
Abstract

BACKGROUND: Hemoglobin-based oxygen carriers hold promise for the treatment of acute anemia.

CASE: We report a patient with severe dysfunctional uterine bleeding. During her hospitalization, her lowest hemoglobin level was 3.1 g/dL, with a hematocrit of 9.3%. An investigational product, o-raffinose cross-linked human hemoglobin solution (hemoglobin raffimer), was infused along with ongoing high-dose recombinant human erythropoietin and estrogen. The time until the patient's own hematopoiesis provided sufficient red blood cell mass was successfully managed by reducing oxygen demand and providing multiple hemoglobin-based oxygen carrier infusions. After hemoglobin-based oxygen carrier administration, transient pulmonary hypertension and fever were noted. She was discharged after corrective surgery 7 days after hemoglobin-based oxygen carrier administration with a hemoglobin level of 7.8 g/dL.

CONCLUSION: The hemoglobin level–based oxygen carrier improved oxygen delivery and permitted uterine corrective surgery.

In Brief

A hemoglobin-based artificial oxygen carrier restored oxygen delivery in a severely anemic patient (lowest hemoglobin level of 3.1 g/dl) with severe uterine bleeding.

Author Information

*Department of Anesthesiology and Critical Care Medicine and †Department of Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; and ‡Department of Anesthesiology and Intensive Care, Freidrich Schiller University, Jena, Germany

Dr. Shander was a Principal Investigator on HLK-213, an investigational trial in cardiac surgery patients, for which he received compensation for patients who completed the protocol.

Address reprint requests to: Aryeh Shander, MD, Department of Anesthesiology and Critical Care Medicine, Englewood Hospital and Medical Center, 350 Engle Street, Englewood, NJ 07631; e-mail: aryeh.shander@ehmc.com

Received June 24, 2003. Received in revised form September 18, 2003. Accepted October 15, 2003.

© 2004 The American College of Obstetricians and Gynecologists